ApicHope Pharmaceutical Future Growth
Future criteria checks 5/6
ApicHope Pharmaceutical is forecast to grow earnings and revenue by 90.3% and 20.5% per annum respectively. EPS is expected to grow by 90.8% per annum. Return on equity is forecast to be 11% in 3 years.
Key information
90.3%
Earnings growth rate
90.8%
EPS growth rate
Pharmaceuticals earnings growth | 18.9% |
Revenue growth rate | 20.5% |
Future return on equity | 11.0% |
Analyst coverage | Low |
Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Revenues Not Telling The Story For ApicHope Pharmaceutical Co., Ltd (SZSE:300723) After Shares Rise 30%
Dec 06Revenues Not Telling The Story For ApicHope Pharmaceutical Co., Ltd (SZSE:300723) After Shares Rise 38%
Oct 09Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?
Jun 27ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year
May 27ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates
May 02ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings
Feb 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,073 | 376 | N/A | 601 | 3 |
12/31/2025 | 2,589 | 378 | N/A | 538 | 3 |
12/31/2024 | 2,166 | 137 | N/A | 330 | 3 |
9/30/2024 | 1,893 | -344 | -416 | -12 | N/A |
6/30/2024 | 2,150 | 26 | 55 | 438 | N/A |
3/31/2024 | 2,410 | 174 | 135 | 480 | N/A |
12/31/2023 | 2,503 | 185 | 124 | 458 | N/A |
9/30/2023 | 2,515 | 307 | 119 | 416 | N/A |
6/30/2023 | 2,641 | 341 | 123 | 511 | N/A |
3/31/2023 | 2,480 | 322 | -21 | 480 | N/A |
1/1/2023 | 2,280 | 291 | -130 | 476 | N/A |
9/30/2022 | 2,161 | 285 | -153 | 511 | N/A |
6/30/2022 | 2,151 | 344 | -157 | 540 | N/A |
3/31/2022 | 2,200 | 319 | -176 | 455 | N/A |
12/31/2021 | 2,199 | 307 | -123 | 438 | N/A |
9/30/2021 | 2,135 | 317 | -133 | 388 | N/A |
6/30/2021 | 1,978 | 263 | -163 | 279 | N/A |
3/31/2021 | 1,851 | 250 | -63 | 341 | N/A |
12/31/2020 | 1,675 | 226 | -39 | 275 | N/A |
9/30/2020 | 1,640 | 173 | -51 | 201 | N/A |
6/30/2020 | 1,515 | 117 | 78 | 249 | N/A |
3/31/2020 | 1,641 | 138 | 28 | 144 | N/A |
12/31/2019 | 1,637 | 144 | 175 | 281 | N/A |
9/30/2019 | 1,537 | 243 | 223 | 301 | N/A |
6/30/2019 | 1,435 | 234 | 169 | 275 | N/A |
3/31/2019 | 1,395 | 219 | 24 | 297 | N/A |
12/31/2018 | 1,430 | 208 | -18 | 239 | N/A |
9/30/2018 | 1,426 | 180 | 23 | 263 | N/A |
6/30/2018 | 1,477 | 167 | N/A | 185 | N/A |
3/31/2018 | 1,467 | 166 | N/A | 186 | N/A |
12/31/2017 | 1,380 | 157 | N/A | 158 | N/A |
9/30/2017 | 1,399 | 156 | N/A | 109 | N/A |
12/31/2016 | 1,251 | 137 | N/A | 146 | N/A |
12/31/2015 | 1,028 | 60 | N/A | 35 | N/A |
12/31/2014 | 793 | 40 | N/A | 9 | N/A |
12/31/2013 | 508 | 33 | N/A | 136 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300723 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 300723 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 300723 is expected to become profitable in the next 3 years.
Revenue vs Market: 300723's revenue (20.5% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 300723's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300723's Return on Equity is forecast to be low in 3 years time (11%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 20:39 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ApicHope Pharmaceutical Co., Ltd is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kehan Meng | Haitong International Research Limited |
Wen Dai | Huatai Research |
Jiaxi Xu | Industrial Securities Co. Ltd. |